<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1333">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01781169</url>
  </required_header>
  <id_info>
    <org_study_id>VD50kIU2011</org_study_id>
    <nct_id>NCT01781169</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation to Obese Chinese Males</brief_title>
  <official_title>Health Effect of Oral Vitamin D Supplementation on Obese Chinese Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Center for Chronic Disease Control</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danone Institute China Diet Nutrition Research and Communication</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Center for Chronic Disease Control</source>
  <oversight_info>
    <authority>China: Chinese Center for Disease Control and Prevention</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Oral Supplementation of Vitamin D can Reduce Hypersecretion of Parathyroid
      Hormone and Insulin Resistance in Obese Chinese Males.

      Protocol: Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) or eight
      weeks to the obese males compared with the normal-weight males. Index measures were
      conducted at baseline and endpoint.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Plasma 25-hydroxy Vitamin D (25(OH)D) Level (Nmol/L)</measure>
    <time_frame>Endpoint and baseline of the 8 weeks' trial</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Obese group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplementation of vitamin D (cholecalciferol), 50000 IU/wk for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal-weight group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplementation of vitamin D (cholecalciferol), 50000 IU/wk for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral supplementation of vitamin D</intervention_name>
    <description>Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) for eight weeks to the obese males compared with the normal-weight males. The chemical form of vitamin D is cholecalciferol capsuled as fine powder.</description>
    <arm_group_label>Obese group</arm_group_label>
    <arm_group_label>Normal-weight group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  body mass index (BMI) ≥ 28kg/m2 or 18.5 ≤ BMI &lt; 24 (kg/m2)

          -  non vegetarian Han Chinese and did not smoke, drink, nor take vitamin D supplements
             for &gt; 2 y

          -  fasting serum glucose &lt; 7.0 mmol/L

          -  serum glucose of 2 hr after 75 g oral glucose loading &lt; 11.1 mmol/L

          -  normal functioning of liver and kidney evaluated by alkaline phosphatase, aspartate
             aminotransferase, creatinine, and uric acid

        Exclusion Criteria:

          -  not match the above inclusion criteria

          -  diagnosed as having any organic diseases were excluded
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji-Chang Zhou, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Center for Chronic Disease Control</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shenzhen Center for Chronic Disease Control</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab. 2011 Mar;96(3):E447-52. doi: 10.1210/jc.2010-2230. Epub 2010 Dec 22.</citation>
    <PMID>21177785</PMID>
  </reference>
  <results_reference>
    <citation>Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet. 1998 Mar 14;351(9105):805-6.</citation>
    <PMID>9519960</PMID>
  </results_reference>
  <results_reference>
    <citation>Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81. Review.</citation>
    <PMID>17634462</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 27, 2013</lastchanged_date>
  <firstreceived_date>January 25, 2013</firstreceived_date>
  <firstreceived_results_date>May 29, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenzhen Center for Chronic Disease Control</investigator_affiliation>
    <investigator_full_name>Zhou Ji-Chang</investigator_full_name>
    <investigator_title>Vice Dean of Molecular Biology Lab</investigator_title>
  </responsible_party>
  <keyword>Vitamin D,</keyword>
  <keyword>Oral supplementation,</keyword>
  <keyword>Obese males</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited at a medical clinic (Health Service Center of Shuiku Community, Shenzhen, China) in May, 2011.</recruitment_details>
      <pre_assignment_details>After enrollment, baseline information of the volunteers including vitamin D nutritional status, health records, etc. were evaluated. Including and excluding criteria were used to select the subjects who were suitable for the intervention trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Obese Group</title>
          <description>Oral supplementation of vitamin D (cholecalciferol), 50000 IU/wk for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Normal-weight Group</title>
          <description>Oral supplementation of vitamin D (cholecalciferol), 50000 IU/wk for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal-weight Group</title>
        </group>
        <group group_id="B2">
          <title>Obese Group</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="41"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34.4" spread="8"/>
                <measurement group_id="B2" value="44.7" spread="8.8"/>
                <measurement group_id="B3" value="39.5" spread="9.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>China</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma 25-hydroxy Vitamin D (25(OH)D) Level (Nmol/L)</title>
        <time_frame>Endpoint and baseline of the 8 weeks' trial</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Obese Group</title>
            <description>Oral supplementation of vitamin D.</description>
          </group>
          <group group_id="O2">
            <title>Normal-weight Group</title>
            <description>Oral supplementation of vitamin D.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma 25-hydroxy Vitamin D (25(OH)D) Level (Nmol/L)</title>
            <units>nmol/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Endpoint plasma 25(OH)D level</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="116.7" spread="20.3"/>
                  <measurement group_id="O2" value="181.3" spread="30.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline plasma 25(OH)D level</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46.1" spread="9.1"/>
                  <measurement group_id="O2" value="52.8" spread="17.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Eight weeks of the trial for all the participants.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Normal-weight Group</title>
        </group>
        <group group_id="E2">
          <title>Obese Group</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The numbers of participants in both the obese group and normal-weight group were small.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ji-Chang Zhou</name_or_title>
      <organization>Shenzhen Center for Chronic Disease Control</organization>
      <phone>86-755-25503842</phone>
      <email>jichangzhou@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
